A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

ClinicalTrials.gov ID: NCT01096043

Public ClinicalTrials.gov record NCT01096043. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa, 3 Strata Dose-Defining Study Evaluating the Hemodynamic Effects, Safety and Tolerability of CXL-1020 in Patients With Systolic Heart Failure

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study CXL-1020-02 employs is designed to further define suitable clinical dosages for CXL-1020 which will be utilized in a later Phase IIb study. The study is conducted in 3 different stages called 'strata" and evaluates the potential utility of this drug for the treatment of patents who are hospitalized with heart failure.

Study identification

NCT ID: NCT01096043
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 69 participants

Conditions and interventions

Conditions

Heart Failure

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2010
Primary completion: Jan 31, 2012
Completion: Jan 31, 2012
Last update posted: Nov 14, 2016

2010 – 2012

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Florida	Gainesville	Florida	32610	—
University of Florida	Jacksonville	Florida	32209	—
Florida Hospital Transplant Center	Orlando	Florida	32804	—
Ochsner Clinic Foundation	New Orleans	Louisiana	70121	—
University of Maryland Medical Center	Baltimore	Maryland	21201	—
DMC Cardiovascular Institute	Detroit	Michigan	48201	—
Henry Ford Health System	Detroit	Michigan	48202	—
University of Medicine & Dentistry of New Jersey - New Jersey Medical School	South Orange	New Jersey	07103	—
Montefiore Medical Center	The Bronx	New York	10467	—
Wake Forest University Health Sciences	Winston-Salem	North Carolina	27157	—
University of Cincinnati	Cincinnati	Ohio	45267	—
University Hospitals Case Medical Center	Cleveland	Ohio	44106	—
Davis Heart & Lung Research Institute	Columbus	Ohio	43210	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
Stern Cardiovascular Center PA	Germantown	Tennessee	38138	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01096043, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 14, 2016 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01096043 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →